Clinical Trial Update: Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis [Phase 2, Phase 3]

View source ↗

Summary

A completed randomized trial evaluated the slow-release TAXUS paclitaxel-eluting coronary stent for treating in-stent restenosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Restenosis
• In-stent Restenosis

Drugs mentioned

• TAXUS Paclitaxel-Eluting Coronary Stent (paclitaxel-eluting coronary stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Restenosis | Phase 2, Phase 3 | Status: COMPLETED